Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + toripalimab
- Development stage
- Phase 3
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + toripalimab is a combination therapy consisting of capecitabine, an oral fluoropyrimidine chemotherapy agent, and toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1 (programmed cell death protein 1). This combination has shown promising antitumor activity and manageable safety profile in clinical trials for nasopharyngeal carcinoma, particularly for residual disease after definitive treatment and as maintenance therapy after first-line treatment.
- Brand names
- Tuoyi
- Other names
- JS001 + capecitabinetoripalimab + capecitabine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + toripalimab.